Bone Short Long Term Debt vs Retained Earnings Analysis

BBLG Stock

USD 1.85 0.17 10.12%

Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Short Long Term Debt and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Short Long Term Debt vs Retained Earnings

Short Long Term Debt vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Short Long Term Debt account and Retained Earnings. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Bone Biologics' Short Long Term Debt and Retained Earnings is -0.5. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Short Long Term Debt and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Bone Biologics Corp are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Short Long Term Debt i.e., Bone Biologics' Short Long Term Debt and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.5

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Short Long Term Debt

The total of a company’s short-term and long-term borrowings.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Bone Biologics' Enterprise Value Over EBITDA is most likely to increase significantly in the upcoming years. The Bone Biologics' current Enterprise Value Multiple is estimated to increase to 0.20, while Selling General Administrative is projected to decrease to 2,394.

Bone Biologics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Other Stockholder Equity	Total Liab	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Net Tangible Assets	Accounts Payable	Long Term Debt	Net Receivables	Non Current Liabilities Total	Inventory	Short Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital
Common Stock Shares Outstanding		-0.39	-0.21	-0.36	-0.42	-0.39	-0.49	-0.34	0.24	0.67	-0.63	-0.51	-0.56	-0.74	-0.39	-0.27	-0.02	-0.2	-0.42	-0.52	-0.08	0.66	-0.15	0.67	-0.51	-0.23
Total Assets	-0.39		-0.65	0.99	0.76	1.0	0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.35	0.72	-0.27	0.44	0.32	-0.57	-0.45	0.39	-0.35	0.38	0.9
Net Debt	-0.21	-0.65		-0.68	-0.34	-0.66	-0.18	0.56	-0.99	-0.02	-0.12	0.89	0.73	0.08	-0.43	0.78	-0.93	0.34	-0.23	0.18	0.81	-0.06	-0.23	-0.14	0.03	-0.8
Cash	-0.36	0.99	-0.68		0.78	0.99	0.66	-0.12	0.64	-0.47	0.62	-0.29	-0.11	0.55	0.7	-0.34	0.73	-0.29	0.46	0.39	-0.57	-0.47	0.44	-0.38	0.43	0.94
Cash And Short Term Investments	-0.42	0.76	-0.34	0.78		0.76	0.71	0.39	0.28	-0.57	0.66	0.04	0.05	0.66	0.92	0.05	0.4	0.19	0.58	0.54	-0.16	-0.62	0.58	-0.48	0.56	0.64
Total Current Assets	-0.39	1.0	-0.66	0.99	0.76		0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.35	0.72	-0.27	0.44	0.32	-0.57	-0.45	0.39	-0.35	0.38	0.9
Other Current Liab	-0.49	0.65	-0.18	0.66	0.71	0.65		0.21	0.08	-0.52	0.6	0.22	0.41	0.57	0.6	-0.06	0.18	0.02	0.43	0.47	-0.02	-0.7	0.07	-0.59	0.35	0.56
Total Current Liabilities	-0.34	-0.11	0.56	-0.12	0.39	-0.11	0.21		-0.6	-0.32	0.24	0.68	0.46	0.38	0.28	0.71	-0.48	0.52	-0.06	0.41	0.31	-0.31	0.16	-0.34	0.32	-0.31
Total Stockholder Equity	0.24	0.62	-0.99	0.64	0.28	0.62	0.08	-0.6		0.07	0.06	-0.92	-0.77	-0.13	0.37	-0.78	0.93	-0.36	0.19	-0.23	-0.82	0.13	0.23	0.2	-0.07	0.77
Retained Earnings	0.67	-0.45	-0.02	-0.47	-0.57	-0.45	-0.52	-0.32	0.07		-0.96	-0.35	-0.33	-0.93	-0.71	-0.27	-0.24	-0.3	-0.76	-0.83	0.05	0.94	-0.5	0.97	-0.89	-0.46
Other Stockholder Equity	-0.63	0.59	-0.12	0.62	0.66	0.59	0.6	0.24	0.06	-0.96		0.23	0.26	0.93	0.74	0.17	0.33	0.22	0.73	0.84	-0.14	-0.92	0.6	-0.92	0.91	0.61
Total Liab	-0.51	-0.25	0.89	-0.29	0.04	-0.25	0.22	0.68	-0.92	-0.35	0.23		0.91	0.45	-0.09	0.78	-0.76	0.32	0.02	0.45	0.72	-0.4	-0.09	-0.45	0.29	-0.49
Common Stock	-0.56	-0.07	0.73	-0.11	0.05	-0.07	0.41	0.46	-0.77	-0.33	0.26	0.91		0.43	-0.12	0.48	-0.63	0.18	0.0	0.44	0.6	-0.4	-0.27	-0.48	0.23	-0.3
Short Long Term Debt Total	-0.74	0.55	0.08	0.55	0.66	0.55	0.57	0.38	-0.13	-0.93	0.93	0.45	0.43		0.69	0.35	0.18	0.29	0.71	0.78	0.03	-0.9	0.55	-0.88	0.84	0.44
Other Current Assets	-0.39	0.67	-0.43	0.7	0.92	0.67	0.6	0.28	0.37	-0.71	0.74	-0.09	-0.12	0.69		-0.04	0.55	0.33	0.77	0.54	-0.25	-0.71	0.61	-0.59	0.63	0.66
Short Term Debt	-0.27	-0.35	0.78	-0.34	0.05	-0.35	-0.06	0.71	-0.78	-0.27	0.17	0.78	0.48	0.35	-0.04		-0.7	0.2	-0.01	0.47	0.6	-0.3	0.3	-0.29	0.36	-0.46
Net Tangible Assets	-0.02	0.72	-0.93	0.73	0.4	0.72	0.18	-0.48	0.93	-0.24	0.33	-0.76	-0.63	0.18	0.55	-0.7		-0.18	0.44	-0.06	-0.83	-0.15	0.31	-0.09	0.15	0.83
Accounts Payable	-0.2	-0.27	0.34	-0.29	0.19	-0.27	0.02	0.52	-0.36	-0.3	0.22	0.32	0.18	0.29	0.33	0.2	-0.18		0.31	0.09	0.33	-0.25	0.07	-0.29	0.22	-0.33
Long Term Debt	-0.42	0.44	-0.23	0.46	0.58	0.44	0.43	-0.06	0.19	-0.76	0.73	0.02	0.0	0.71	0.77	-0.01	0.44	0.31		0.51	0.07	-0.77	0.53	-0.67	0.63	0.47
Net Receivables	-0.52	0.32	0.18	0.39	0.54	0.32	0.47	0.41	-0.23	-0.83	0.84	0.45	0.44	0.78	0.54	0.47	-0.06	0.09	0.51		0.15	-0.8	0.57	-0.84	0.91	0.36
Non Current Liabilities Total	-0.08	-0.57	0.81	-0.57	-0.16	-0.57	-0.02	0.31	-0.82	0.05	-0.14	0.72	0.6	0.03	-0.25	0.6	-0.83	0.33	0.07	0.15		-0.1	-0.12	-0.06	0.0	-0.69
Inventory	0.66	-0.45	-0.06	-0.47	-0.62	-0.45	-0.7	-0.31	0.13	0.94	-0.92	-0.4	-0.4	-0.9	-0.71	-0.3	-0.15	-0.25	-0.77	-0.8	-0.1		-0.46	0.95	-0.82	-0.45
Short Long Term Debt	-0.15	0.39	-0.23	0.44	0.58	0.39	0.07	0.16	0.23	-0.5	0.6	-0.09	-0.27	0.55	0.61	0.3	0.31	0.07	0.53	0.57	-0.12	-0.46		-0.33	0.75	0.44
Property Plant Equipment	0.67	-0.35	-0.14	-0.38	-0.48	-0.35	-0.59	-0.34	0.2	0.97	-0.92	-0.45	-0.48	-0.88	-0.59	-0.29	-0.09	-0.29	-0.67	-0.84	-0.06	0.95	-0.33		-0.82	-0.37
Current Deferred Revenue	-0.51	0.38	0.03	0.43	0.56	0.38	0.35	0.32	-0.07	-0.89	0.91	0.29	0.23	0.84	0.63	0.36	0.15	0.22	0.63	0.91	0.0	-0.82	0.75	-0.82		0.43
Net Invested Capital	-0.23	0.9	-0.8	0.94	0.64	0.9	0.56	-0.31	0.77	-0.46	0.61	-0.49	-0.3	0.44	0.66	-0.46	0.83	-0.33	0.47	0.36	-0.69	-0.45	0.44	-0.37	0.43

Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	12.2K	12.1K	18.9K	47.6K	263.1K	250.0K
Total Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Net Debt	11.3M	11.7M	(6.7M)	(7.5M)	(3.0M)	(2.9M)
Cash	24.1K	0.0	6.7M	7.5M	3.0M	2.0M
Cash And Short Term Investments	955.4K	24.1K	6.7M	7.5M	3.0M	2.1M
Liabilities And Stockholders Equity	1.0M	30.8K	6.7M	8.5M	3.7M	2.5M
Total Current Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Other Current Liab	513.7K	535.6K	1.5M	2.5M	470.7K	447.2K
Total Current Liabilities	578.4K	13.7M	99.9K	2.5M	831.4K	789.8K
Total Stockholder Equity	(11.9M)	(13.7M)	6.6M	5.9M	2.9M	3.1M
Retained Earnings	(67.0M)	(68.9M)	(70.5M)	(72.0M)	(80.9M)	(76.9M)
Total Liab	11.9M	13.7M	99.9K	2.5M	831.4K	789.8K
Short Long Term Debt Total	8.2M	9M	11.3M	11.7M	13.5M	8.3M
Other Current Assets	105.2K	85.3K	6.7K	956.9K	711.2K	746.8K
Net Tangible Assets	(8.6M)	(11.9M)	(13.7M)	6.6M	7.6M	7.9M
Accounts Payable	42.9K	465.4K	99.9K	888.46	360.7K	202.9K
Non Current Liabilities Total	8.2M	0.0	11.3M	12.2M	99.9K	888.46
Net Invested Capital	(547.6K)	(2.0M)	6.6M	5.9M	2.9M	2.1M
Net Working Capital	(547.6K)	(13.7M)	6.6M	5.9M	2.9M	3.1M

Pair Trading with Bone Biologics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bone Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bone Biologics will appreciate offsetting losses from the drop in the long position's value.

Moving against Bone Stock

0.84	MCK	McKesson Earnings Call This Week	Pair Corr
0.78	VKTX	Viking Therapeutics	Pair Corr
0.75	OMI	Owens Minor Earnings Call Today	Pair Corr
0.74	GCTK	GlucoTrack	Pair Corr
0.69	CI	Cigna Corp	Pair Corr

The ability to find closely correlated positions to Bone Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bone Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bone Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bone Biologics Corp to buy it.

The correlation of Bone Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bone Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bone Biologics Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bone Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:

How To Invest In Bone

Details

Is Bone Stock a good investment?

Details

What is Bone Biologics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for Bone Stock analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.

	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Transaction History View history of all your transactions and understand their impact on performance
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins

Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(34.01)

Return On Assets

(0.96)

Return On Equity

(2.02)

The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bone Short Long Term Debt vs Retained Earnings Analysis

Short Long Term Debt vs Retained Earnings

Short Long Term Debt vs Retained Earnings Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Retained Earnings

Bone Biologics fundamental ratios Correlations

Bone Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bone Biologics fundamental ratios Accounts

Pair Trading with Bone Biologics

Moving against Bone Stock

Complementary Tools for Bone Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Property Plant Equipment	+ 0.97	Retained Earnings
Property Plant Equipment	+ 0.95	Inventory
Net Invested Capital	+ 0.94	Cash

Total Stockholder Equity	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Short Long Term Debt Total	- 0.93	Retained Earnings
Net Tangible Assets	- 0.93	Net Debt
Property Plant Equipment	- 0.92	Other Stockholder Equity
Inventory	- 0.92	Other Stockholder Equity